Abstract
Adrenergic mechanisms are involved in the formation of several types of pulmonary edema (PE) such as neurogenic pulmonary edema (NPE) or PE in patients with pheochromocytoma, but also in the development of pulmonary fibrosis and pulmonary hypertension. In severe cases of PE such as in the adult respiratory distress syndrome (ARDS), PE is typically accompanied by inflammation and followed by pulmonary vascular hypertrophy and pulmonary fibrosis. Norepinephrine and other adrenoceptor agonists are known to provoke activation of proinflammatory cytokines such as interleukin (IL)-1 and IL-6. These cytokines are involved both in the pathogenesis of PE and of pulmonary fibrosis. We therefore assume that adrenergic mechanisms may have an important role in the pathogenesis of pulmonary injuries characterized by edema, inflammation and fibrosis. The contribution of adrenoceptor stimulation, particularly the distinct role of α- and β-adrenergic mechanisms, to the development of PE and pulmonary fibrosis is reviewed in this paper.
Keywords: Acute lung injury, adrenergic agonists, adrenergic antagonists, isoproterenol, norepinephrine, pulmonary edema, pulmonary inflammation, pulmonary fibrosis, phenylephrine, sympathetic stimulation.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Role of α- and β-adrenergic Mechanisms in the Pathogenesis of Pulmonary Injuries Characterized by Edema, Inflammation and Fibrosis
Volume: 13 Issue: 3
Author(s): Beate Rassler
Affiliation:
Keywords: Acute lung injury, adrenergic agonists, adrenergic antagonists, isoproterenol, norepinephrine, pulmonary edema, pulmonary inflammation, pulmonary fibrosis, phenylephrine, sympathetic stimulation.
Abstract: Adrenergic mechanisms are involved in the formation of several types of pulmonary edema (PE) such as neurogenic pulmonary edema (NPE) or PE in patients with pheochromocytoma, but also in the development of pulmonary fibrosis and pulmonary hypertension. In severe cases of PE such as in the adult respiratory distress syndrome (ARDS), PE is typically accompanied by inflammation and followed by pulmonary vascular hypertrophy and pulmonary fibrosis. Norepinephrine and other adrenoceptor agonists are known to provoke activation of proinflammatory cytokines such as interleukin (IL)-1 and IL-6. These cytokines are involved both in the pathogenesis of PE and of pulmonary fibrosis. We therefore assume that adrenergic mechanisms may have an important role in the pathogenesis of pulmonary injuries characterized by edema, inflammation and fibrosis. The contribution of adrenoceptor stimulation, particularly the distinct role of α- and β-adrenergic mechanisms, to the development of PE and pulmonary fibrosis is reviewed in this paper.
Export Options
About this article
Cite this article as:
Rassler Beate, Role of α- and β-adrenergic Mechanisms in the Pathogenesis of Pulmonary Injuries Characterized by Edema, Inflammation and Fibrosis, Cardiovascular & Hematological Disorders-Drug Targets 2013; 13 (3) . https://dx.doi.org/10.2174/1871529X1303140129154602
DOI https://dx.doi.org/10.2174/1871529X1303140129154602 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Is the Cytoskeleton an Intracellular Receptor for Adrenomedullin and PAMP?
Current Protein & Peptide Science Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Current Molecular Medicine Permeation Studies of Captopril Transdermal Films Through Human Cadaver Skin
Current Drug Delivery Aldosterone, Mineralocorticoid Receptor and the Metabolic Syndrome:Role of the Mineralocorticoid Receptor Antagonists
Current Vascular Pharmacology Treatments for Obesity-Related Hypertension
Current Hypertension Reviews Cyclic Nucleotide and Protein Kinase Signaling in Hypertensive Pulmonary Arterial Smooth Muscle
Current Respiratory Medicine Reviews Role of ω3 Longchain Polyunsaturated Fatty Acids in Reducing Cardio- Metabolic Risk Factors
Endocrine, Metabolic & Immune Disorders - Drug Targets New Drugs for Epidural Analgesia
Current Drug Targets Vascular Effects of Insulin and Their Relation to Endothelial Dysfunction, Insulin Resistance and Hypertension
Current Hypertension Reviews Inotropic and Vasoactive Drugs in Pediatric ICU
Current Drug Targets TRPV1 Function in Health and Disease
Current Pharmaceutical Biotechnology Adiponectin and its Role in Cardiovascular Diseases
Cardiovascular & Hematological Disorders-Drug Targets Recent Advances in Management of Diabetic Macular Edema
Current Diabetes Reviews The Pamela Study: Old and New Findings
Current Hypertension Reviews Phosphoinositide-3 Kinase Signaling in Cardiac Hypertrophy and Heart Failure
Current Pharmaceutical Design Functional Calixarenes for Material and Life Science
Current Organic Chemistry Marine Bioactive Peptides as Potential Antioxidants
Current Protein & Peptide Science Phytochemical Therapies in Vascular Functioning: A Molecular Approach
Current Vascular Pharmacology Neuro-Psychological Pattern in Patients Suffering from Primitive Dilated Cardiomyopathy with Impairment in Executive Function
Current Neurovascular Research The Role of Apelins in the Physiology of the Heart
Protein & Peptide Letters